JP2009502931A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502931A5
JP2009502931A5 JP2008524072A JP2008524072A JP2009502931A5 JP 2009502931 A5 JP2009502931 A5 JP 2009502931A5 JP 2008524072 A JP2008524072 A JP 2008524072A JP 2008524072 A JP2008524072 A JP 2008524072A JP 2009502931 A5 JP2009502931 A5 JP 2009502931A5
Authority
JP
Japan
Prior art keywords
compound
composition
pharmaceutically acceptable
acceptable salt
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/028875 external-priority patent/WO2007016108A1/en
Publication of JP2009502931A publication Critical patent/JP2009502931A/ja
Publication of JP2009502931A5 publication Critical patent/JP2009502931A5/ja
Pending legal-status Critical Current

Links

JP2008524072A 2005-07-27 2006-07-24 体重減少を促すための組成物 Pending JP2009502931A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70287705P 2005-07-27 2005-07-27
PCT/US2006/028875 WO2007016108A1 (en) 2005-07-27 2006-07-24 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
JP2009502931A JP2009502931A (ja) 2009-01-29
JP2009502931A5 true JP2009502931A5 (cg-RX-API-DMAC7.html) 2009-09-10

Family

ID=37198787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524072A Pending JP2009502931A (ja) 2005-07-27 2006-07-24 体重減少を促すための組成物

Country Status (12)

Country Link
US (1) US20070117827A1 (cg-RX-API-DMAC7.html)
EP (1) EP1907005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009502931A (cg-RX-API-DMAC7.html)
KR (1) KR20080042092A (cg-RX-API-DMAC7.html)
CN (1) CN101237886A (cg-RX-API-DMAC7.html)
AU (1) AU2006275914A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613911A2 (cg-RX-API-DMAC7.html)
CA (1) CA2614539A1 (cg-RX-API-DMAC7.html)
IL (1) IL188442A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008001136A (cg-RX-API-DMAC7.html)
RU (1) RU2007147609A (cg-RX-API-DMAC7.html)
WO (1) WO2007016108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
AU2009249071A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT3222280T (pt) 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물

Similar Documents

Publication Publication Date Title
RU2007147609A (ru) Составы для эффективной потери веса
RU2007103313A (ru) Комбинация бупропина и другого состава для эффективной потери веса
US8404749B2 (en) Method of inhibiting inflammatory pain
EA200200291A1 (ru) Производные биариловых эфиров, полезные в качестве ингибиторов обратного захвата моноамина
PE28695A1 (es) Composicion para la potenciacion de la respuesta farmacologica
AR108614A2 (es) Composiciones y métodos para reducir antojos de comer
DE60120748D1 (de) 3-substituierte oxindolderivate als beta-3-agonisten
JP2013521286A5 (cg-RX-API-DMAC7.html)
EA200100748A1 (ru) Ингибиторы обратного захвата моноаминов для лечения расстройств цнс
JP2009541489A5 (cg-RX-API-DMAC7.html)
JP2006526031A5 (cg-RX-API-DMAC7.html)
JP2012521429A5 (cg-RX-API-DMAC7.html)
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2012521428A5 (cg-RX-API-DMAC7.html)
RU2008135264A (ru) Терапевтическое средство для воспалительных заболеваний кишечника, содержащее в качестве активного ингредиента производное 2-амино-1,3-пропандиола, или способ лечения воспалительных заболеваний кишечника
BRPI0500585A (pt) Processo para a sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
CY1112911T1 (el) Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο
RU2005132453A (ru) Составы, вызывающие потерю веса
JP2005536503A5 (cg-RX-API-DMAC7.html)
IL183061A0 (en) Aryloxyethylamine derivatives with a combination of partial dopamine d2 receptor agonism and serotonin reuptake inhibition
JP2011529502A5 (cg-RX-API-DMAC7.html)
NO20091464L (no) Heterocykliske forbindelser anvendelige som anaboliske midler for buskapsdyr
JP2009539822A5 (cg-RX-API-DMAC7.html)
JP2009521470A5 (cg-RX-API-DMAC7.html)